198 related articles for article (PubMed ID: 33443508)
1. Combination of mitochondria targeting doxorubicin with Bcl-2 function-converting peptide NuBCP-9 for synergistic breast cancer metastasis inhibition.
Yang J; Li Q; Zhou R; Zhou M; Lin X; Xiang Y; Xie D; Huang Y; Zhou Z
J Mater Chem B; 2021 Feb; 9(5):1336-1350. PubMed ID: 33443508
[TBL] [Abstract][Full Text] [Related]
2. Combined effects of naringin and doxorubicin on the JAK/STAT signaling pathway reduce the development and spread of breast cancer cells.
Effat H; Abosharaf HA; Radwan AM
Sci Rep; 2024 Feb; 14(1):2824. PubMed ID: 38310190
[TBL] [Abstract][Full Text] [Related]
3. Synergistic antitumor effects of Peiminine and Doxorubicin on breast cancer through enhancing DNA damage via ZEB1.
Xu J; Zhang Z; Hu H; Yang Y; Xiao C; Xi L; Lu J; Tian S; Zhao H
Biomed Pharmacother; 2024 Apr; 173():116353. PubMed ID: 38432128
[TBL] [Abstract][Full Text] [Related]
4. Synergistic effects of ozone with doxorubicin on the proliferation, apoptosis and metastatic profile of luminal-B type human breast cancer cell line.
Karagülle OO; Yurttaş AG
Tissue Cell; 2023 Dec; 85():102233. PubMed ID: 37866151
[TBL] [Abstract][Full Text] [Related]
5. In Vivo Investigation of Supportive Immunotherapeutic Combination of Bifidobacterium infantis 35624 and Doxorubicin in Murine Breast Cancer.
Akbaba M; Gökmen GG; Kışla D; Nalbantsoy A
Probiotics Antimicrob Proteins; 2023 Aug; 15(4):880-888. PubMed ID: 35112297
[TBL] [Abstract][Full Text] [Related]
6. Induction of apoptosis and suppression of tumor growth by Nur77-derived Bcl-2 converting peptide in chemoresistant lung cancer cells.
Pearce MC; Gamble JT; Kopparapu PR; O'Donnell EF; Mueller MJ; Jang HS; Greenwood JA; Satterthwait AC; Tanguay RL; Zhang XK; Kolluri SK
Oncotarget; 2018 May; 9(40):26072-26085. PubMed ID: 29899843
[TBL] [Abstract][Full Text] [Related]
7. Targeting the Opening of Mitochondrial Permeability Transition Pores Potentiates Nanoparticle Drug Delivery and Mitigates Cancer Metastasis.
Lin X; Li L; Li S; Li Q; Xie D; Zhou M; Huang Y
Adv Sci (Weinh); 2021 Feb; 8(4):2002834. PubMed ID: 33643797
[TBL] [Abstract][Full Text] [Related]
8. Combination Therapy in Cancer: Doxorubicin in Combination with an N-terminal Peptide of Endostatin Suppresses Angiogenesis and Stimulates Apoptosis in the Breast Cancer.
Sarabi N; Chamani R; Assareh E; Saberi O; Asghari SM
Int J Mol Cell Med; 2023; 12(2):120-134. PubMed ID: 38313376
[TBL] [Abstract][Full Text] [Related]
9. Precision targeting of CuET overload to disrupt mitochondrial unfolded protein response by integrated liposome.
Yin X; Wu B; Yang Y; Shi J; Fu Y; Zhang H; Ye J; Sun Y; Chen C; Zhu Y; Zhang W
Int J Biol Macromol; 2024 Mar; 262(Pt 1):129974. PubMed ID: 38331068
[TBL] [Abstract][Full Text] [Related]
10. Rational design of mitochondria-targeted fluorescent biosensors for in vivo elucidation of the interaction between breast cancer metastasis and mitochondrial autophagy.
Yuan L; Cao Y; Zhang Q; Pan J; Wu C; Ye Y; Jiao Q; Zhu HL; Wang Z
Biosens Bioelectron; 2024 May; 251():116123. PubMed ID: 38359670
[TBL] [Abstract][Full Text] [Related]
11. Therapy-induced normal tissue damage promotes breast cancer metastasis.
Perkins DW; Steiner I; Haider S; Robertson D; Buus R; O'Leary L; Isacke CM
iScience; 2024 Jan; 27(1):108503. PubMed ID: 38161426
[TBL] [Abstract][Full Text] [Related]
12.
Rainone P; De Palma A; Sudati F; Roffia V; Rigamonti V; Salvioni L; Colombo M; Ripamonti M; Spinelli AE; Mazza D; Mauri P; Moresco RM; Prosperi D; Belloli S
Int J Nanomedicine; 2021; 16():1943-1960. PubMed ID: 33727808
[TBL] [Abstract][Full Text] [Related]
13. Nongenotoxic ABCB1 activator tetraphenylphosphonium can contribute to doxorubicin resistance in MX-1 breast cancer cell line.
Kubiliute R; Januskeviciene I; Urbanaviciute R; Daniunaite K; Drobniene M; Ostapenko V; Daugelavicius R; Jarmalaite S
Sci Rep; 2021 Mar; 11(1):6556. PubMed ID: 33753859
[TBL] [Abstract][Full Text] [Related]
14. Tumour-Targeted and Redox-Responsive Mesoporous Silica Nanoparticles for Controlled Release of Doxorubicin and an siRNA Against Metastatic Breast Cancer.
Zhuang J; Chen S; Hu Y; Yang F; Huo Q; Xie N
Int J Nanomedicine; 2021; 16():1961-1976. PubMed ID: 33727809
[TBL] [Abstract][Full Text] [Related]
15. Brain metastasis with subtype conversion in a patient with male breast cancer: A case report.
Oh BH; Woo CG; Lee YJ; Park YS
Medicine (Baltimore); 2021 Mar; 100(11):e24373. PubMed ID: 33725931
[TBL] [Abstract][Full Text] [Related]
16. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.
Rugo HS; Lerebours F; Ciruelos E; Drullinsky P; Ruiz-Borrego M; Neven P; Park YH; Prat A; Bachelot T; Juric D; Turner N; Sophos N; Zarate JP; Arce C; Shen YM; Turner S; Kanakamedala H; Hsu WC; Chia S
Lancet Oncol; 2021 Apr; 22(4):489-498. PubMed ID: 33794206
[TBL] [Abstract][Full Text] [Related]
17. Advances in Therapeutic Approaches for Triple-Negative Breast Cancer.
Mahtani R; Kittaneh M; Kalinsky K; Mamounas E; Badve S; Vogel C; Lower E; Schwartzberg L; Pegram M;
Clin Breast Cancer; 2021 Oct; 21(5):383-390. PubMed ID: 33781662
[TBL] [Abstract][Full Text] [Related]
18. Patient-Reported Outcomes in Patients With
Ciruelos EM; Rugo HS; Mayer IA; Levy C; Forget F; Delgado Mingorance JI; Safra T; Masuda N; Park YH; Juric D; Conte P; Campone M; Loibl S; Iwata H; Zhou X; Park J; Ridolfi A; Lorenzo I; André F
J Clin Oncol; 2021 Jun; 39(18):2005-2015. PubMed ID: 33780274
[TBL] [Abstract][Full Text] [Related]
19. The oncogene AAMDC links PI3K-AKT-mTOR signaling with metabolic reprograming in estrogen receptor-positive breast cancer.
Golden E; Rashwan R; Woodward EA; Sgro A; Wang E; Sorolla A; Waryah C; Tie WJ; Cuyàs E; Ratajska M; Kardaś I; Kozlowski P; Johnstone EKM; See HB; Duffy C; Parry J; Lagerborg KA; Czapiewski P; Menendez JA; Gorczyński A; Wasag B; Pfleger KDG; Curtis C; Lee BK; Kim J; Cursons J; Pavlos NJ; Biernat W; Jain M; Woo AJ; Redfern A; Blancafort P
Nat Commun; 2021 Mar; 12(1):1920. PubMed ID: 33772001
[TBL] [Abstract][Full Text] [Related]
20. Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase II clinical trial.
Masuda N; Bando H; Yamanaka T; Kadoya T; Takahashi M; Nagai SE; Ohtani S; Aruga T; Suzuki E; Kikawa Y; Yasojima H; Kasai H; Ishiguro H; Kawabata H; Morita S; Haga H; Kataoka TR; Uozumi R; Ohno S; Toi M
Breast Cancer Res Treat; 2021 Jul; 188(1):117-131. PubMed ID: 33763789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
